Consensus BioLife Solutions, Inc.

Equities

BLFS

US09062W2044

Market Closed - Nasdaq 04:00:00 2024-04-26 pm EDT 5-day change 1st Jan Change
17.53 USD +3.97% Intraday chart for BioLife Solutions, Inc. +10.53% +7.88%

Evolution of the average Target Price on BioLife Solutions, Inc.

Price target over the last 5 years

History of analyst recommendation changes

dcdf704.RpYYEdkzSr7IGpVWeEBdPGemDhtVDufBEKq6w5dvpOA.NvRheOlSP_esed44KHkuSlLwRikRQp-ZYMTTgvwY95kK9Sl6r1sC3Z1coQ~f9cdc0470a41e8febe227b1844a75a44
Jefferies Initiates Coverage on BioLife Solutions With Buy Rating, $22 Price Target MT
Lake Street Adjusts BioLife Solutions Price Target to $15 From $25, Maintains Buy Rating MT
Lake Street Adjusts Price Target on BioLife Solutions to $25 From $34, Maintains Buy Rating MT
Stephens Adjusts BioLife Solutions Price Target to $29 From $27, Maintains Overweight Rating MT
Craig-Hallum Starts BioLife Solutions at Buy With $29 Price Target MT
BioLife Solutions, Inc. Launches the IntelliRate i67C Liquid Nitrogen Controlled-Rate Freezer CI
B. Riley Trims BioLife Solutions' Price Target to $33 From $34, Keeps Buy Rating MT
Stephens Trims Price Target on BioLife Solutions to $27 From $31, Maintains Overweight Rating MT
B. Riley Lowers BioLife Solutions' Price Target to $34 from $48, Keeps Buy Rating MT
KeyBanc Lowers BioLife Solutions Price Target to $30 From $60, Overweight Rating Kept MT
Oppenheimer Upgrades BioLife Solutions to Outperform From Perform, $28 Price Target MT
B. Riley Lowers BioLife Solutions' PT to $48 from $67, Raises Discount Rate Due to Increasing Cost of Capital, Return Expectation; Maintains Buy Rating MT
BIOLIFE : Cowen Adjusts BioLife Solutions' Price Target to $64 From $50, Keeps Outperform Rating MT
BIOLIFE : KeyBanc Adjusts BioLife Solutions' Price Target to $60 From $50, Reiterates Overweight Rating MT
BIOLIFE : Benchmark Downgrades BioLife Solutions to Hold From Buy MT
BioLife Solutions, Inc. Launches New High Capacity Controlled Rate Freezer Line with First Shipment to a Leading Cell Therapy Developer CI
BIOLIFE : B Riley Raises BioLife Solutions' PT to $61 from $35.50 After Q4 Revenue Beats Street, Announces Stirling Ultracold Deal; Keeps Buy Rating MT
BIOLIFE : Maxim Adjusts Price Target on BioLife Solutions to $60 From $40, Maintains Buy Rating MT
BIOLIFE : Stephens Adjusts BioLife Solutions' Price Target to $55 From $50, Maintains Overweight Rating MT
BIOLIFE : KeyBanc Adjusts BioLife Solutions' Price Target to $50 From $40, Keeps Overweight Rating MT
BIOLIFE : Benchmark Upgrades BioLife Solutions to Buy From Hold; Price Target is $54 MT
BIOLIFE : Northland Adjusts Price Target on BioLife Solutions to $55 From $35, Keeps Outperform Rating MT
BIOLIFE : KeyBanc Starts BioLife Solutions at Overweight with $40 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
17.53 USD
Average target price
23.12 USD
Spread / Average Target
+31.92%
High Price Target
30 USD
Spread / Highest target
+71.14%
Low Price Target
20 USD
Spread / Lowest Target
+14.09%

Consensus detail

Consensus revision (last 18 months)

Analysts covering BioLife Solutions, Inc.

Jefferies & Co.
Lake Street
Stephens Inc.
Craig-Hallum
B. Riley
KeyBanc Capital Markets
Oppenheimer
Cowen
Benchmark Capital
Maxim
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
  1. Stock Market
  2. Equities
  3. BLFS Stock
  4. Consensus BioLife Solutions, Inc.